Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects.
暂无分享,去创建一个
Nick C Fox | M. Rossor | R. Scahill | S. Cousens | R. Harvey
[1] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[2] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[3] J V Haxby,et al. Rate of ventricular enlargement in dementia of the Alzheimer type correlates with rate of neuropsychological deterioration , 1987, Neurology.
[4] B. Kirkwood. Essentials of medical statistics. , 1988 .
[5] A. Burns,et al. Computed tomography in Alzheimer's disease: A longitudinal study , 1991, Biological Psychiatry.
[6] J. Haxby,et al. Longitudinal changes in lateral ventricular volume in Datients with dementia of the Alzheimer type , 1992, Neurology.
[7] J. Mazziotta,et al. Rapid Automated Algorithm for Aligning and Reslicing PET Images , 1992, Journal of computer assisted tomography.
[8] M. Albert,et al. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. , 1993, Archives of neurology.
[9] C. Cuénod,et al. Amygdala atrophy in Alzheimer's disease. An in vivo magnetic resonance imaging study. , 1993, Archives of neurology.
[10] Gwenn S. Smith,et al. The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. , 1993, AJNR. American journal of neuroradiology.
[11] S Lehéricy,et al. Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease. , 1994, AJNR. American journal of neuroradiology.
[12] Gastone G. Celesia,et al. A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .
[13] A. Smith,et al. Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease , 1994, The Lancet.
[14] J A Yesavage,et al. Longitudinal volumetric computed tomographic analysis of regional brain changes in normal aging and Alzheimer's disease. , 1995, Archives of neurology.
[15] Hans Förstl,et al. Brain Atrophy in Normal Ageing and Alzheimer's Disease , 1995, British Journal of Psychiatry.
[16] A. Smith,et al. Use of structural imaging to study the progression of Alzheimer's disease. , 1996, British medical bulletin.
[17] Nick C Fox,et al. Visualisation and quantification of rates of atrophy in Alzheimer's disease , 1996, The Lancet.
[18] Nick C Fox,et al. Accurate registration of serial 3D MR brain images and its application to visualizing change in neurodegenerative disorders. , 1996, Journal of computer assisted tomography.
[19] K. Davis,et al. The search for disease-modifying treatment for Alzheimer's disease , 1997, Neurology.
[20] S. Birge. The role of estrogen in the treatment of Alzheimer's disease , 1997, Neurology.
[21] P Woodbury,et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.
[22] G. Fein,et al. Tissue segmentation of the brain in Alzheimer disease. , 1997, AJNR. American journal of neuroradiology.
[23] Nick C Fox,et al. Cerebral and cerebellar atrophy on serial magnetic resonance imaging in an initially symptom free subject at risk of familial prion disease , 1997, BMJ.
[24] C. Jack,et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease , 1997, Neurology.
[25] J. Kaye,et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia , 1997, Neurology.
[26] W F Stewart,et al. Risk of Alzheimer's disease and duration of NSAID use , 1997, Neurology.
[27] Nick C Fox,et al. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. , 1997, Computer methods and programs in biomedicine.
[28] P Leber,et al. Slowing the progression of Alzheimer disease: methodologic issues. , 1997, Alzheimer disease and associated disorders.
[29] R J Harvey,et al. Drug treatments for Alzheimer's disease , 1997, BMJ.
[30] R. Mohs,et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.
[31] C. Jack,et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease , 1998, Neurology.
[32] J. Kaye,et al. Brain volume preserved in healthy elderly through the eleventh decade , 1998, Neurology.
[33] B. Gulanski,et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease , 1998, Neurology.
[34] Rachelle S. Doody,et al. DONEPEZIL STUDY GROUP. A 24-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF DONEPEZIL IN PATIENTS WITH ALZHEIMER'S DIS-EASE , 1998 .
[35] B. Gulanski,et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease , 1998, Neurology.
[36] M N Rossor,et al. Correlation between rates of brain atrophy and cognitive decline in AD , 1999, Neurology.
[37] M. Woodward. Drug Treatments for Alzheimer's Disease , 1999 .